At a glance
- Originator Nonindustrial source
- Class Antiplatelets
- Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors; Thromboxane A2 receptor antagonists; Thromboxane B2 antagonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 23 Sep 1998 No-Development-Reported for Thrombosis in Taiwan (Unknown route)
- 13 Nov 1996 New profile
- 13 Nov 1996 Preclinical development for Thrombosis in Taiwan (Unknown route)